Lineage Cell Therapeutics, Inc. SEC filings LCTX
Lineage Cell Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jul 3, 2012. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 23, 2026 | — |
| CORRESP | Letter to the SEC | Mar 19, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2026 | — |
| EFFECT | Filing | May 14, 2024 | — |
| EFFECT | Filing | Mar 19, 2021 | — |
| EFFECT | Filing | Mar 19, 2021 | — |
| CORRESP | Letter to the SEC | Mar 17, 2021 | — |
| CORRESP | Letter to the SEC | Mar 17, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2021 | — |
| EFFECT | Filing | May 8, 2020 | — |
| CORRESP | Letter to the SEC | May 6, 2020 | — |
| UPLOAD | Letter from the SEC | May 6, 2020 | — |
| 425 | Filing | Mar 1, 2019 | — |
| 425 | Filing | Dec 6, 2018 | — |
| 425 | Filing | Dec 6, 2018 | — |
| 425 | Filing | Nov 9, 2018 | — |
| 425 | Filing | Nov 8, 2018 | — |
| 425 | Filing | Nov 8, 2018 | — |
| 25-NSE | Delisting notice | Sep 27, 2018 | — |
| CT ORDER | Filing | Dec 14, 2017 | — |
| CT ORDER | Filing | Sep 12, 2017 | — |
| DEFR14A | Filing | Jul 13, 2017 | — |
| PRER14A | Filing | Jun 30, 2017 | — |
| EFFECT | Filing | Jun 28, 2017 | — |
| CORRESP | Letter to the SEC | Jun 27, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 22, 2017 | — |
| EFFECT | Filing | May 5, 2017 | — |
| CORRESP | Letter to the SEC | May 3, 2017 | — |
| CORRESP | Letter to the SEC | May 2, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 18, 2017 | — |
| CT ORDER | Filing | Jun 24, 2016 | — |
| CT ORDER | Filing | May 23, 2016 | — |
| EFFECT | Filing | Jan 25, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 21, 2016 | — |
| CORRESP | Letter to the SEC | Jan 20, 2016 | — |
| CT ORDER | Filing | Nov 23, 2015 | — |
| CT ORDER | Filing | Jul 7, 2015 | — |
| CT ORDER | Filing | May 29, 2015 | — |
| EFFECT | Filing | Feb 12, 2015 | — |
| CT ORDER | Filing | Jan 22, 2015 | — |
| CT ORDER | Filing | Jan 22, 2015 | — |
| D | Filing | Mar 7, 2014 | — |
| EFFECT | Filing | Feb 6, 2014 | — |
| CT ORDER | Filing | Dec 19, 2013 | — |
| EFFECT | Filing | Sep 27, 2013 | — |
| 8-A12B | Biotime 8-a12b 9-23-2013 | Sep 24, 2013 | — |
| CORRESP | Letter to the SEC | Sep 24, 2013 | — |
| CORRESP | Letter to the SEC | Aug 21, 2013 | — |
| EFFECT | Filing | Jul 31, 2013 | — |
| CORRESP | Letter to the SEC | Jul 29, 2013 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2013 | — |
| CORRESP | Letter to the SEC | Jun 27, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2013 | — |
| CORRESP | Letter to the SEC | Apr 2, 2013 | — |
| PRER14A | Biotime, inc prer 14a 5-21-2013 | Apr 2, 2013 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2013 | — |
| EFFECT | Filing | Jan 11, 2013 | — |
| DFAN14A | Current report | Jan 8, 2013 | — |
| CORRESP | Letter to the SEC | Jan 8, 2013 | — |
| DFAN14A | Definitive additional proxy soliciting materials filed by non-management | Jan 7, 2013 | — |
| CORRESP | Letter to the SEC | Dec 21, 2012 | — |
| CORRESP | Letter to the SEC | Dec 11, 2012 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2012 | — |
| 425 | Biotime, inc. 425 | Oct 18, 2012 | — |
| EFFECT | Filing | Sep 7, 2012 | — |
| EFFECT | Filing | Aug 17, 2012 | — |
| CORRESP | Letter to the SEC | Aug 14, 2012 | — |
| CORRESP | Letter to the SEC | Aug 14, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2012 | — |
| DEL AM | Biotime inc del am 8-3-2012 | Aug 6, 2012 | — |
| CT ORDER | Filing | Jul 24, 2012 | — |
Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LCTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 876343
- Former names
- BIOTIME INC (until Aug 8, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.